Amrutha. N, Anand. P, Swathy K. R, Anila K N, Suresh Kumar R
firstname.lastname@example.org , email@example.com
Amrutha. N1, Anand. P2, Swathy K. R3, Anila K N4*, Suresh Kumar R5
1,2,3Students, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Kerala, Amrita Vishwa Vidyapeetham, India.
4Lecturer, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Kerala, Amrita Vishwa Vidyapeetham, India.
5Clinical Professor, Department of Neurology, Amrita Institute of Medical Sciences, Amrita Health Sciences Campus, Koch, Kerala, Amrita Vishwa Vidyapeetham, India.
Volume - 13,
Issue - 12,
Year - 2020
Multiple sclerosis is the most common chronic autoimmune neurodegenerative disorder of the Central Nervous System (CNS), which occurs due to the destruction in myelin sheath of the nerve fibres. AIM: To study the clinical profile and treatment pattern of patients with multiple sclerosis attending in a tertiary care hospital. This was a retrospective, observational study conducted at the department of Neurology in Amrita institute of Medical Science and Research Centre for a period of one year. The list of patients with MS attended neurology department during JAN 2005 to JUN 2017 was obtained from Amrita Health Information System (AHIS) support team of AIMS on requisition. The patients satisfying exclusion and inclusion were selected from the obtained list. A total case of 43 patients with multiple sclerosis were analysed. The minimum age of onset was 6years and the male to female ratio was found to be 1:2.3. Most common symptoms shown by patients are muscular issues (69.8%) and sensory disturbance (67.4%), and the other symptoms are visual disturbance (48.8%), bladder issues (30.2%), cognitive problems (14%) and the headache, walking difficulty, ataxia, and balance disorder were the least common symptoms shown. RRMS was found in 76.74%, SPMS in 16.3%, PPMS in 4.7% and PRMS in 2.3% of cases with one-time relapse in majority. Major therapy included Oral (76.7%) and IV (37.2%) corticosteroids and immunomodulatory agents like interferon beta 1a (18%) and azathioprine (9.3%). Drugs for neuropathic pain, bladder issues, cognitive issues like amitriptyline, pregabalin, tolterodine, piracetam, dimethyl fumarate etc., were also prescribed. Our study observed a predominant form of relapsing remitting multiple sclerosis with female preponderance. Majority patients had one-time relapse with more than one lesion especially in periventricular white matter and had complaints of muscle weakness and sensory disturbances. Treatment pattern had shown the wide use of corticosteroids in oral and IV form and addition of immunomodulatory agents like Interferon beta 1a. Since the exact cause of the disease is still unknown, treatment provided to the patients were based on their symptoms.
Cite this article:
Amrutha. N, Anand. P, Swathy K. R, Anila K N, Suresh Kumar R. A Study on the Assessment of clinical profile and treatment pattern of multiple Sclerosis in a Tertiary care Hospital. Research J. Pharm. and Tech. 2020; 13(12):6066-6072. doi: 10.5958/0974-360X.2020.01057.4
1. Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis. Neuropsychology review. 1998 Jun 1;8(2):43-77.
2. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996 May 3;85(3):299-302.
3. Goldenberg MM. Multiple sclerosis review. Pharmacy and Therapeutics. 2012 Mar;37(3):175.
4. Metz L. Multiple sclerosis: symptomatic therapies. In Seminars in neurology 1998 (Vol. 18, No. 03, pp. 389-395). © 1998 by Thieme Medical Publishers, Inc.
5. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgraduate Medical Journal. 2005 May 1;81(955):302-8.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996 Apr 1;46(4):907-11.
7. Calabresi PA. Diagnosis and management of multiple sclerosis. American family physician. 2004 Nov 15;70(10):1935-44.
8. Adam AL, Morgan MR, Lindsey WT. A review and treatment option updates multiple Sclerosis: Alabama Pharmacy Association. Continuing Education. August 31, 2014.
9. Pandit L, Subramanya R, RaoSN. Multiple sclerosis in coastal Karnataka. Neurology India.1993;41(3):143-6.
10. Kuroiwa Y, Kurland LT (eds): Multiple Sclerosis East and West. Asian Multiple Sclerosis Workshop, Kyoto, September 1981 / Satellite Symposium Multiple Sclerosis and 12th World Congress of Neurology, Kyoto, September 1981: Proceedings. Basel, Karger, 1982, pp 31-42.
11. Mathew NT, Mathai KV, Abraham J, Taori GM. Incidence and pattern of demyelinating disease in India. Journal of the neurological sciences. 1971 May 1;13(1):27-38.
12. Sanaie BA, Zahwa B, Singh H. Clinical Profile of Multiple Sclerosis in Kashmir (India): A Tertiary Care Hospital Based Study. International Journal of Scientific Study. 2017 Feb 1;4(11):103-6.
13. Gangopadhyay G, Das SK, Sarda P, Saha SP, Gangopadhyay P, Roy TN, Maity B. Clinical profile of multiple sclerosis in Bengal. Neurology India. 1999 Jan 1;47(1):18.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg‐Wollheim M. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2001 Jul;50(1):121-7.
15. BarkhofF, Smithuis R, Hazewinkel M. Multiple sclerosis. Radiology assistant. Department of Diagnostic Radiology, Vrinje Universiteit Hospital, Amsterdam, The Netherland. Available from http://www.radiologyassistant.nl/en/p4556dea65db62/multiple-sclerosis.html
16. Burje S, Rungta S, Shukla A. Detection and Classification of MRI Brain Images for Head/Brain Injury Using Soft Computing Techniques. Research Journal of Pharmacy and Technology. 2017;10(3):715-20.
17. Deisenhammer F, Zetterberg H, Fitzner B and Zettl UK. The Cerebrospinal Fluid in Multiple Sclerosis. Front. Immunol. 12 April 2019. doi: 10.3389/fimmu.2019.00726
18. Palace J. Making the diagnosis of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2001 Dec 1;71(suppl 2): ii3-8.
19. Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences. 2015 Oct;20(4):329.
20. Gouda V, Shastry CS, Mateti UV, Subrahmanya C, Chand S. Study on Steroid Utilization Patterns in General Medicine Department. Research Journal of Pharmacy and Technology. 2019;12(10):4771-6.
21. Lekshmi RS, Shanmugasundaram P. Neuroprotective Properties of Statins. Research Journal of Pharmacy and Technology. 2018;11(8):3581-4.
22. Chabas D, Fontaine B, Lyon-Caen O. Multiple Sclerosis, Orphanet Encyclopedia. July 2004.
23. Ghosh S, Pahari S, Roy T. An updated overview on food supplement. Asian Journal of Research in Chemistry. 2018; 11(3): 691-7.
24. Subashree R, Arjunkumar R. Vitamin D Deficiency in Periodontal Health. Research Journal of Pharmacy and Technology. 2014;7(2):248-52.
25. Khokra SL, Parashar B, Dhamija HK, Bala M. Immunomodulators: Immune System Modifiers. Research Journal of Pharmacy and Technology. 2012;5(2):169-74.
26. Litvinova EV, Posilkina OV, Maslova NF. Formation of patent strategy at all stages of biosimilar development and Implementation. Research Journal of Pharmacy and Technology. 2018;11(7):3081-6.
27. Siniscalchi A, Gallelli L, De Sarro G. Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis. Clinical drug investigation. 2013 Feb 1;33(2):151-4.
28. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database of Systematic Reviews. 2007(4).
29. Clausen J, Jensen GE, Nielsen SA. Selenium in chronic neurologic diseases. In Selenium 1988 (pp. 179-203). Humana Press.
30. Patel VK, Kpatel C, Patel HU, Patel CN. Vitamins, Minerals and Carotenoids as a Antioxidants. Asian Journal of Research in Chemistry. 2010;3(2):255-60.
31. Popova NF, Kamchatnov PR, Riabukhina OV, Batysheva TT, Zaĭtsev KA, Boĭko AN. Omaron in the complex treatment of patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 2010;110(11 Pt 1):17-20.
32. Asadi-Pooya AA. Phenytoin for neuroprotection. The Lancet Neurology. Available from: www.thelancet.com/neurology. August 2016;15(9)
33. Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, Rao CM. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Asian Journal of Pharmacy and Technology. 2017;7(3):137-43
34. Bomprezzi R. Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Therapeutic advances in neurological disorders. 2015 Jan;8(1):20-30.
35. Zhornitsky S, Wee Yong V, Koch MW, Mackie A, Potvin S, Patten SB, Metz LM. Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. CNS neuroscience & therapeutics. 2013 Oct;19(10):737-44.
36. Kopsky DJ, Liebregts R, Keppel Hesselink JM. Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case reports in medicine. 2012;2012.
37. Tsau S, Emerson MR, Lynch SG, LeVine SM. Aspirin and multiple sclerosis. BMC medicine. 2015 Dec;13(1):153.
38. Damm J, Eser D, Moeller HJ, Rupprecht R. Severe dependency on zolpidem in a patient with multiple sclerosis suffering from paraspasticity.The World Journal of Biological Psychiatry. 2010 Mar1;11(2-2):516-8.
39. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. The Lancet Neurology. 2005 Oct 1;4(10):643-52.
40. Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology. 2014 Feb 1;22(1):1-22.
41. Khochage SR, Bhutkar MA, Mali SD, Todkar SB. Formulation and Evaluation of Pulsincap of Tramadol HCl for the Treatment of Rheumatoid arthritis. Research Journal of Pharmacy and Technology. 2013;6(10):1137-40.
42. Bagur MJ, Murcia MA, Jiménez-Monreal AM, Tur JA, Bibiloni MM, Alonso GL, Martínez-Tomé M. Influence of diet in multiple sclerosis: a systematic review. Advances in nutrition. 2017 May;8(3):463-72.
43. Cawello W, Stockis A, Andreas JO, Dimova S. Advances in epilepsy treatment: Lacosamide Pharmacokinetic Profile. Annals of the New York Academy of Sciences. 2014 Nov;1329(1):18-32.